CONTENTS

PERSPECTIVE

CYP1A Induction and Human Risk Assessment: An Evolving Tale of In Vitro and In Vivo Studies. Qiang Ma and Anthony Y. H. Lu .................. 1009

SHORT COMMUNICATION


ARTICLES

Esterase Inhibition Attribute of Grapefruit Juice Leading to a New Drug Interaction. Ping Li, Patrick S. Callery, Liang-Shang Gan, and Suresh K. Balani ..................... 1023

Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways. Lukas Cerveny, Lucie Svecova, Eva Anzenbacherova, Radim Vrzal, Frantisek Staud, Zdenek Dvorak, Jitka Ulrichova, Pavel Anzenbacher, and Petr Pavek ...................... 1032

Biotransformation of 6-Methoxy-3-(3’,4’,5’-trimethoxy-benzoyl)-1H-indole (BPR0L075), a Novel Antimicrotubule Agent, by Mouse, Rat, Dog, and Human Liver Microsomes. Hsien-Tsung Yao, Yu-Shan Wu, Yi-Wei Chang, Hsing-Pang Hsieh, Wei-Cheng Chen, Shih-Jung Lan, Chiung-Tong Chen, Yu-Sheng Chao, Ling Chang, Hsu-Yi Sun, and Teng-Kuang Yeh ............ 1042

Possible Bioactivation Pathways of Lamotrigine. Wei Lu and Jack P. Uetrecht .................. 1050

Effect of Perinatal Low Protein Diets on the Ontogeny of Select HepaticCytochrome P450 Enzymes and Cytochrome P450 Reductase in the Rat. Ganesh Cherala, Bernard H. Shapiro, and Anil P. D’mello .................... 1057


Metabolism, Pharmacokinetics, and Excretion of a Nonpeptidic Substance P Receptor Antagonist, Ezlopitant, in Normal Healthy Male Volunteers: Characterization of Polar Metabolites by Chemical Derivatization with Dnsyl Chloride. Chandrika Prakash, John O’Donnell, and S. Cyrus Khojasteh-Bakht .................. 1071

Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes. Ping Kang, Deepak Dalvie, Evan Smith, Sue Zhou, and Alan Deese ............ 1081

Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum. Kenji Masaki, Mitsuru Hashimoto, and Teruko Inai ............ 1089

Continued on next page

Selective Tissue Distribution of Tibolone Metabolites in Mature Ovariectomized Female Cynomolgus Monkeys after Multiple Doses of Tibolone. H. A. M. Verheul, M. L. P. van Iersel, L. P. C. Delbressine, and H. J. Kloosterboer .................................. 1105

Pharmacokinetic Parameters of Tibolone and Metabolites in Plasma, Urine, Feces, and Bile from Ovariectomized Cynomolgus Monkeys after a Single Dose or Multiple Doses of Tibolone. H. A. M. Verheul, C. J. Timmer, M. L. P. S. van Iersel, L. P. C. Delbressine, and H. J. Kloosterboer .................................................. 1112

Application of the Dispersion Model to Describe Disposition Kinetics of Markers in the Dual Perfused Rat Liver. Selma Sahin and Malcolm Rowland ........................................ 1119

Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor α. Valerie Y. Ng, Yong Huang, L. Mannmohan Reddy, John R. Falck, Emil T. Lin, and Deanna L. Krott .................................................. 1126

Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6. MarjoVolotinen, Miia Turpeinen, Ari Tolonen, Jouko Uusitalo, Jakka Mäenpää, and Olavi Pelkonen .......................... 1135

Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xeno-biotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients. Tetsuo Yamagata, Hiroyuki Kusuhara, Mariko Morishita, Kozo Takayama, Hassan Benameur, and Yuichi Sugiyama ........................................ 1142

The Prokinetic Cinitapride Has No Clinically Relevant Pharmacokinetic Interaction and Effect on QT during Coadministration with Ketoconazole. Marta Robert, Miguel Salvà, Rosa Segarra, Marco Pavesi, Ramón Esbrí, David Roberts, and Georg Golor .................................................. 1149


Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine. Guoyu Pan, Nagdeep Giri, and William F. Elmquist ........................................ 1165

CYP2C9 Protein Interactions with Cytochrome b_{5}; Effects on the Coupling of Catalysis. Charles W. Locuston, Larry C. Wienkers, Jeffrey P. Jones, and Timothy S. Tracy ............. 1174

Predominant Contribution of UDP-Glucuronosyl-transferase 2B7 in the Glucuronidation of Race-mic Flurbiprofen in the Human Liver. Yuji Mano, Takashi Usui, and Hidetaka Kamimura ........ 1182

Metabolism and Disposition of a Selective α_{1} Nicotinic Acetylcholine Receptor Agonist in Humans. Christopher L. Shaffer, Mithat Gunduz, Renato J. Scialis, and Annie F. Fang ........................................ 1188

Absorption, Metabolism, and Excretion of [^{14}C]MK-0524, a Prostaglandin D_{2} Receptor Antagonist, in Humans. Bindhu Karanam, Maria Madeira, Scott Bradley, Larissa Wenning, Rajesh Desai, Eric Soli, David Schenk, Allen Jones, Brian Dean, George Doss, Graigrey Garrett, Tami Crumley, Ajay Nirula, and Eseng Lai ................................. 1196

Esterase Inhibition by Grapefruit Juice Flavonoids Leading to a New Drug Interaction. Ping Li, Patrick S. Callery, Liang-Shang Gan, and Suresh K. Balani ........................................ 1203

Impact of Genetic Knockout of PEPT2 on Cefadroxil Pharmacokinetics, Renal Tubular Reabsorption, and Brain Penetration in Mice. Hong Shen, Scott M. Ocheltree, Yongjin Hu, Richard F. Keep, and David E. Smith ........................................ 1209

Selective Toxicity of Aristolochic Acids I and II. Shinya Shibutani, Huan Dong, Naomi Suzuki, Shiro Ueda, Frederick Miller, and Arthur P. Grollman .................................................. 1217


Isolation and Characterization of Polyspecific Mouse Organic Solute Carrier Protein 1 (mOscp1). Yasuna Kobayashi, Ayumi Tsu-chiya, Tomofumi Hayashi, Noriko Kohyama, Masayuki Ohbayashi, and Toshinori Yamamoto ............................. 1239

ERRATUM

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: A diagram showing the relationship between % remaining and the therapeutic blood or plasma concentration of 171 marketed compounds in which in vivo DDI information was incorporated. See the article by Watanabe et al. in this issue on page 1232.